JP2005510244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005510244A5 JP2005510244A5 JP2003547621A JP2003547621A JP2005510244A5 JP 2005510244 A5 JP2005510244 A5 JP 2005510244A5 JP 2003547621 A JP2003547621 A JP 2003547621A JP 2003547621 A JP2003547621 A JP 2003547621A JP 2005510244 A5 JP2005510244 A5 JP 2005510244A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- expression construct
- vaccine
- flavivirus
- sequence encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000710831 Flavivirus Species 0.000 claims 21
- 235000018102 proteins Nutrition 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 102000004169 proteins and genes Human genes 0.000 claims 18
- 229960005486 vaccine Drugs 0.000 claims 17
- 239000002773 nucleotide Substances 0.000 claims 14
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 239000004365 Protease Substances 0.000 claims 13
- 241001465754 Metazoa Species 0.000 claims 11
- 239000013604 expression vector Substances 0.000 claims 10
- 230000002163 immunogen Effects 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 230000035772 mutation Effects 0.000 claims 8
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 7
- 108020004414 DNA Proteins 0.000 claims 6
- 230000005867 T cell response Effects 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 6
- 230000036039 immunity Effects 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 5
- 230000002458 infectious effect Effects 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 101710189818 Non-structural protein 2a Proteins 0.000 claims 4
- 108010067390 Viral Proteins Proteins 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 229940024606 amino acid Drugs 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 241000710912 Kunjin virus Species 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 230000007969 cellular immunity Effects 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 238000004806 packaging method and process Methods 0.000 claims 3
- 230000001681 protective effect Effects 0.000 claims 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- 101710117545 C protein Proteins 0.000 claims 2
- 101710204837 Envelope small membrane protein Proteins 0.000 claims 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- 101710145006 Lysis protein Proteins 0.000 claims 2
- 101800000512 Non-structural protein 1 Proteins 0.000 claims 2
- 101800001030 Non-structural protein 2A Proteins 0.000 claims 2
- 101710144111 Non-structural protein 3 Proteins 0.000 claims 2
- 101800001020 Non-structural protein 4A Proteins 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800000508 Non-structural protein 5 Proteins 0.000 claims 2
- 101710144121 Non-structural protein 5 Proteins 0.000 claims 2
- 101800000980 Protease nsP2 Proteins 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 241000710960 Sindbis virus Species 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 210000004102 animal cell Anatomy 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 230000007774 longterm Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 claims 1
- 101710177291 Gag polyprotein Proteins 0.000 claims 1
- 101710125418 Major capsid protein Proteins 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 150000002614 leucines Chemical class 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR9093A AUPR909301A0 (en) | 2001-11-26 | 2001-11-26 | Flavivirus vaccine system |
| AU2002950974A AU2002950974A0 (en) | 2002-07-29 | 2002-07-29 | Flavivirus vaccine system |
| PCT/AU2002/001598 WO2003046189A1 (en) | 2001-11-26 | 2002-11-26 | Flavivirus vaccine delivery system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005510244A JP2005510244A (ja) | 2005-04-21 |
| JP2005510244A5 true JP2005510244A5 (enExample) | 2006-01-19 |
Family
ID=25646850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003547621A Pending JP2005510244A (ja) | 2001-11-26 | 2002-11-26 | フラビウイルスワクチン送達系 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060204523A1 (enExample) |
| EP (1) | EP1461441A4 (enExample) |
| JP (1) | JP2005510244A (enExample) |
| CN (1) | CN100392087C (enExample) |
| CA (1) | CA2467397A1 (enExample) |
| NZ (1) | NZ533237A (enExample) |
| WO (1) | WO2003046189A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004072274A1 (en) * | 2003-01-30 | 2004-08-26 | Shanghai Tengen Biomedical Co., Ltd. | Virus-like particle vaccine containing dengue virus recombinant replicon as its carrier |
| AU2004245578B2 (en) * | 2003-06-06 | 2008-10-30 | Replikun Biotech Pty Ltd | Flavivirus replicon packaging system |
| AU2003902842A0 (en) * | 2003-06-06 | 2003-06-26 | The University Of Queensland | Flavivirus replicon packaging system |
| CN1304579C (zh) * | 2003-07-21 | 2007-03-14 | 上海天甲生物医药有限公司 | 重组的以黄热病病毒为载体的疫苗 |
| US20070036827A1 (en) * | 2003-10-29 | 2007-02-15 | The University Of Queensland | West nile virus vaccine |
| WO2007098267A2 (en) * | 2006-02-27 | 2007-08-30 | The Board Of Regents Of The University Of Texas System | Pseudoinfectious flavivirus and uses thereof |
| WO2009114207A2 (en) * | 2008-03-14 | 2009-09-17 | Sanofi Pasteur Biologics Co. | Replication-defective flavivirus vaccines and vaccine vectors |
| CA2755257A1 (en) * | 2009-03-16 | 2010-09-23 | Sanofi Pasteur Biologics Co. | Replication-defective flavivirus vaccine vectors against respiratory syncytial virus |
| CA2804591C (en) * | 2010-07-06 | 2019-01-22 | Novartis Ag | Cationic oil-in-water emulsions |
| SI2714071T1 (sl) * | 2011-05-24 | 2019-11-29 | Biontech Rna Pharmaceuticals Gmbh | Individualizirana cepiva proti raku |
| LT2714071T (lt) | 2011-05-24 | 2019-10-10 | Biontech Rna Pharmaceuticals Gmbh | Individualizuotos vakcinos nuo vėžio |
| WO2013019603A2 (en) * | 2011-07-29 | 2013-02-07 | Inovio Pharmaceuticals, Inc. | Linear expression cassettes and uses thereof |
| EP3105311A1 (en) | 2014-02-10 | 2016-12-21 | Univercells NV | System, apparatus and method for biomolecules production |
| EP3352785A1 (en) * | 2015-09-23 | 2018-08-01 | Massachusetts Institute Of Technology | Compositions and methods for modified dendrimer nanoparticle vaccine delivery |
| WO2018152158A1 (en) * | 2017-02-14 | 2018-08-23 | Shi Pei Yong | Live attenuated zika virus with 3'utr deletion, vaccine containing and use thereof |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| AU2020395091A1 (en) * | 2019-12-03 | 2022-07-28 | The Council Of The Queensland Institute Of Medical Research | Defective interfering particles |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| ES2345614T3 (es) * | 1997-02-28 | 2010-09-28 | Sanofi Pasteur Biologics Co. | Vacunas quimericas de flavivirus. |
| NZ504725A (en) * | 1997-11-28 | 2003-02-28 | Crown In The Right Of The Quee | Flavivirus expression and delivery system |
| US6893866B1 (en) * | 1997-11-28 | 2005-05-17 | The Crown In The Right Of The Queensland Department Of Health | Flavivirus expression and delivery system |
| WO2000014245A1 (en) * | 1998-09-02 | 2000-03-16 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | Dengue viruses that are replication defective in mosquitos for use as vaccines |
| FR2794865B1 (fr) * | 1999-06-09 | 2003-04-18 | Pasteur Institut | Methode de detection precoce des flavivirus et ses applications |
| CA2380302C (en) * | 1999-08-09 | 2013-02-26 | Biochemie Gesellschaft M.B.H. | Production of proteins by autoproteolytic cleavage |
| US6589531B1 (en) * | 2000-01-21 | 2003-07-08 | The Regents Of The University Of California | Recombinant yellow fever virus and method of use thereof |
| DK2278012T3 (en) * | 2000-02-16 | 2015-12-07 | Us Government | Immunogenic dengue 2 virus chimeras |
| US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
-
2002
- 2002-11-26 CN CNB028275624A patent/CN100392087C/zh not_active Expired - Fee Related
- 2002-11-26 NZ NZ533237A patent/NZ533237A/en unknown
- 2002-11-26 JP JP2003547621A patent/JP2005510244A/ja active Pending
- 2002-11-26 US US10/496,421 patent/US20060204523A1/en not_active Abandoned
- 2002-11-26 EP EP02779017A patent/EP1461441A4/en not_active Ceased
- 2002-11-26 CA CA002467397A patent/CA2467397A1/en not_active Abandoned
- 2002-11-26 WO PCT/AU2002/001598 patent/WO2003046189A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5538729B2 (ja) | 偽感染性フラビウイルスおよびそれらの使用 | |
| JP4504464B2 (ja) | キメラフラビウイルスワクチン | |
| JP4656794B2 (ja) | 無毒性の免疫原性フラビウイルスキメラ | |
| Gehrke et al. | Incorporation of tick-borne encephalitis virus replicons into virus-like particles by a packaging cell line | |
| US20100086564A1 (en) | West Nile Virus Vaccine | |
| EP1751289A1 (en) | Tc-83-derived alphavirus vectors, particles and methods | |
| RU2527891C2 (ru) | Флавивирус с двухкомпонентным геномом и его использование | |
| EP1366170A1 (en) | Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents | |
| AU2002235678A1 (en) | Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents | |
| Bonaldo et al. | Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus | |
| US20250099568A1 (en) | Chimeric Flavivirus Lyssavirus Vaccines | |
| CN100392087C (zh) | 黄病毒疫苗输送系统 | |
| CN101018860A (zh) | 黄病毒疫苗 | |
| JP2006526393A5 (enExample) | ||
| WO2004072274A1 (en) | Virus-like particle vaccine containing dengue virus recombinant replicon as its carrier | |
| WO2005040390A1 (en) | A recombinant vaccine using yellow fever virus as vector | |
| JP7663250B2 (ja) | ラッサウイルスワクチン | |
| RU2816136C2 (ru) | Химерные вакцины на основе вирусов родов flavivirus и lyssavirus | |
| CN111343998B (zh) | 哺乳动物特异性的生长缺陷的虫媒病毒 | |
| Roby et al. | Nucleic acid-based infectious and pseudo-infectious flavivirus vaccines | |
| US20220402976A1 (en) | Chimeric filovirus vaccines | |
| OA20659A (en) | Chimeric filovirus vaccines. | |
| HK1083192B (en) | West nile virus vaccine |